(1 reference)-
- Target See all EGFRviii (EGFRv3) products
- EGFRviii (EGFRv3) (EGFR vIII (EGFRv3))
- Sequence
- One-letter code: LEEKKGNYVV TDHC, Three-letter code: {Leu}{Glu}{Glu}{Lys}{Lys}{Gly}{Asn}{Tyr}{Val}{Val}{Thr}{Asp}{His}{Cys
- Purity
- > 95 %
-
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Storage
- -20 °C
-
-
: "EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma." in: Cancer research, Vol. 70, Issue 15, pp. 6303-12, (2010) (PubMed).
-
: "EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma." in: Cancer research, Vol. 70, Issue 15, pp. 6303-12, (2010) (PubMed).
-
- Target
- EGFRviii (EGFRv3) (EGFR vIII (EGFRv3))
- Background
- The epidermal growth factor receptor variant III (EGFRvIII) is a consistent tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms. As such it represents a truly tumor-specific target for antitumor immunotherapy.
- Molecular Weight
- 1634.82
-
You are here:
